18 Jul CPTx
Hendrik Dietz, CEO
Oct. 5 | 3:15pm | FLW Ballroom G
Munich, Germany
(Private)
CPTx is developing a non-viral, duration-tunable platform for in vivo CAR-T therapies. The approach combines immune-quiet DNA vectors encoding CAR genes with targeted lipid nanoparticles for delivery to T cells. CPTx’s DNA vectors can generate both time-limited, transient CAR-T responses and long-lasting, durable expression, while also supporting multi-gene payloads. This flexibility enables the development of therapies across oncology, autoimmune diseases, and other indications. Durable expression is particularly important for cancer, while a transient burst of CAR-T activity can support immune-reset applications in autoimmune diseases. CPTx has purpose-built every layer of the platform, including proprietary immune-quiet and duration-tunable DNA vectors, custom LNP formulations, and targeting strategies that direct the payload to T cells. The company has demonstrated B-cell depletion and tumor killing both in vitro and in vivo.